Addex Therapeutics (ADXN) EBIAT (2022 - 2025)
Historic EBIAT for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to -$2.0 million.
- Addex Therapeutics' EBIAT fell 1182.67% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.6 million, marking a year-over-year increase of 9999.97%. This contributed to the annual value of $8.0 million for FY2024, which is 16823.63% up from last year.
- Addex Therapeutics' EBIAT amounted to -$2.0 million in Q3 2025, which was down 1182.67% from -$2.4 million recorded in Q2 2025.
- Addex Therapeutics' EBIAT's 5-year high stood at -$579883.9 during Q2 2023, with a 5-year trough of -$3536.9 billion in Q1 2024.
- For the 4-year period, Addex Therapeutics' EBIAT averaged around -$235.8 billion, with its median value being -$2.6 million (2023).
- As far as peak fluctuations go, Addex Therapeutics' EBIAT tumbled by 13590096289.68% in 2024, and later skyrocketed by 10000.0% in 2025.
- Quarter analysis of 4 years shows Addex Therapeutics' EBIAT stood at -$21.6 million in 2022, then skyrocketed by 86.95% to -$2.8 million in 2023, then crashed by 98.83% to -$5.6 million in 2024, then surged by 64.82% to -$2.0 million in 2025.
- Its EBIAT stands at -$2.0 million for Q3 2025, versus -$2.4 million for Q2 2025 and -$1.6 million for Q1 2025.